Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $206 from $200 and keeps an Equal Weight rating on the shares. The company reported a Q1 revenue and earnings beat and maintained its 2026 guidance when excluding IPR&D spend, the analyst tells investors in a research note. the firm added that BIIB080 Phase 2 Alzheimer’s data and Litifilimab Phase 3 SLE data represent the next key pipeline catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Kept at Hold as Near-Term Growth Remains Constrained; Market Perform with Unchanged $196 Price Target
- Biogen price target raised to $222 from $213 at RBC Capital
- Andrew Fein Reiterates Buy on Biogen, Lifts Price Target to $237 on De‑Risked BIIB080 Alzheimer’s Opportunity
- Biogen price target raised to $196 from $191 at Wedbush
- Biogen price target raised to $260 from $246 at Guggenheim